Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma

[1]  Zhen Wang,et al.  Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta‐analysis , 2018, Hepatology.

[2]  M. Murad,et al.  Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta‐analysis , 2018, Hepatology.

[3]  P. Galle,et al.  The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. , 2017, Journal of hepatology.

[4]  L. Dawson,et al.  Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. , 2017, Journal of hepatology.

[5]  Chao Zhang,et al.  Characterization of slow cycling corneal limbal epithelial cells identifies putative stem cell markers , 2017, Scientific Reports.

[6]  W. Guo,et al.  Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection , 2017, Journal of Cancer.

[7]  D. Weitz,et al.  An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma , 2017, Proceedings of the National Academy of Sciences.

[8]  W. Guo,et al.  Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection , 2016, Clinical chemistry and laboratory medicine.

[9]  Masatoshi Kudo,et al.  Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment , 2016, Liver Cancer.

[10]  Jiansheng Li,et al.  Overexpression of ANXA3 is an independent prognostic indicator in gastric cancer and its depletion suppresses cell proliferation and tumor growth , 2016, Oncotarget.

[11]  Jiekai Yu,et al.  High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers , 2016, Oncotarget.

[12]  Ya Cao,et al.  Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. , 2016, Gastroenterology.

[13]  R. Finn,et al.  Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection , 2016, Liver Cancer.

[14]  J. Bruix,et al.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. , 2016, Journal of hepatology.

[15]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[16]  K. Pan,et al.  Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma , 2015, Molecular carcinogenesis.

[17]  K. Chan,et al.  ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma , 2015, Stem cell reports.

[18]  Yan Li,et al.  Annexin A3 Is a Potential Predictor of Platinum Resistance in Epithelial Ovarian Cancer Patients in a Prospective Cohort , 2015, Journal of Cancer.

[19]  Yan Tang,et al.  Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem‐Like Cells , 2015, Stem cells.

[20]  W. Guo,et al.  Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[21]  W. Guo,et al.  Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform , 2014, Clinical Cancer Research.

[22]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[23]  W. Guo,et al.  Circulating stem cell–like epithelial cell adhesion molecule–positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection , 2013, Hepatology.

[24]  N. Wu,et al.  The role of annexin A3 playing in cancers , 2013, Clinical and Translational Oncology.

[25]  T. Seki,et al.  Annexin A3 as a negative regulator of adipocyte differentiation. , 2012, Journal of biochemistry.

[26]  Hongyang Wang,et al.  Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. , 2012, The Lancet. Oncology.

[27]  Yili Yang,et al.  Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients , 2012, Journal of cellular and molecular medicine.

[28]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[29]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[30]  J. Bruix,et al.  Prognostic prediction and treatment strategy in hepatocellular carcinoma , 2002, Hepatology.

[31]  P. Johnson,et al.  The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. , 2001, Clinics in liver disease.

[32]  H. Pollard,et al.  Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. , 1994, Biochimica et biophysica acta.

[33]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[34]  H. Klocker,et al.  Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. , 2009, The Journal of urology.